[go: up one dir, main page]

TR200201638T2 - Yeni imidazo[1,3,5]triazinonlar ve kullanımları - Google Patents

Yeni imidazo[1,3,5]triazinonlar ve kullanımları

Info

Publication number
TR200201638T2
TR200201638T2 TR2002/01638T TR200201638T TR200201638T2 TR 200201638 T2 TR200201638 T2 TR 200201638T2 TR 2002/01638 T TR2002/01638 T TR 2002/01638T TR 200201638 T TR200201638 T TR 200201638T TR 200201638 T2 TR200201638 T2 TR 200201638T2
Authority
TR
Turkey
Prior art keywords
triazinones
new imidazo
imidazo
new
phosphodiesterases
Prior art date
Application number
TR2002/01638T
Other languages
English (en)
Inventor
Niew�Hner Ulrich
Haning Helmut
Lampe Thomas
Es-Sayed Mazen
Schmidt Gunter
Bischoff Erwin
Dembowsky Klaus
Perzborn Elisabeth
Schlemmer Karl-Heinz
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999162928 external-priority patent/DE19962928A1/de
Priority claimed from DE10003323A external-priority patent/DE10003323A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of TR200201638T2 publication Critical patent/TR200201638T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Bu bulus yeni imidazo[1,3,5]triazinonlar'a, üretimleri için bir yönteme ve ilaç olarak özellikle siklik GMP metaboliklestirici fosfodiesterazlarin inhibitörleri olarak kullanimlarina iliskindir.
TR2002/01638T 1999-12-24 2000-12-12 Yeni imidazo[1,3,5]triazinonlar ve kullanımları TR200201638T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999162928 DE19962928A1 (de) 1999-12-24 1999-12-24 Neue Imidazo[1,3,5]triazinone und ihre Verwendung
DE10003323A DE10003323A1 (de) 2000-01-27 2000-01-27 Neue Imidazo[1,3,5[triazinone und ihre Verwendung

Publications (1)

Publication Number Publication Date
TR200201638T2 true TR200201638T2 (tr) 2002-11-21

Family

ID=26004043

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01638T TR200201638T2 (tr) 1999-12-24 2000-12-12 Yeni imidazo[1,3,5]triazinonlar ve kullanımları

Country Status (13)

Country Link
US (2) US6803365B2 (tr)
EP (1) EP1244673A2 (tr)
JP (1) JP2003519150A (tr)
KR (1) KR20020062770A (tr)
CN (1) CN1434825A (tr)
AU (1) AU781028B2 (tr)
BR (1) BR0017043A (tr)
CA (1) CA2395548A1 (tr)
IL (1) IL150022A0 (tr)
MX (1) MXPA02006240A (tr)
PL (1) PL356848A1 (tr)
TR (1) TR200201638T2 (tr)
WO (1) WO2001047928A2 (tr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135462A0 (en) * 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
CN1434825A (zh) * 1999-12-24 2003-08-06 拜尔公司 咪唑并[1,3,5]三嗪酮及其应用
WO2002009713A2 (de) * 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
BR0209541A (pt) * 2001-05-09 2004-04-20 Bayer Healthcare Ag Uso das imidazotriazinonas 2-fenil-substituìdas
GB0126417D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Crystal structure
BRPI0307802B8 (pt) * 2002-02-22 2021-05-25 Merck Sharp & Dohme formulação farmacêutica compreendendo temozolomida, processo para a produção da mesma, bem como artigo fabricado contendo pó liofilizado compreendendo temozolomida
DE10224462A1 (de) * 2002-06-03 2003-12-11 Bayer Ag Verwendung von cGMP stimulierenden Verbindungen
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
CN1548438A (zh) * 2003-05-16 2004-11-24 烟台开发区北方药物研究所 2-取代苯基-6,8-二烃基-3H-咪唑[1,5α][1,3,5]三嗪-4-酮衍生物,其制备方法及其药物用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
NZ547528A (en) * 2003-10-29 2008-11-28 Elan Pharm Inc N-substituted benzene sulfonamides
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
EP1850853A4 (en) * 2005-02-18 2011-09-07 Surface Logix Inc PHARMACOKINETICALLY IMPROVED COMPOUNDS
NZ560962A (en) * 2005-02-18 2011-12-22 Surface Logix Inc Methods of making pharmacokinetically improved compounds using sarcosine functional residues or groups and pharmaceutical compositions comprising said compounds
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
RU2435588C2 (ru) * 2005-09-29 2011-12-10 Байер Шеринг Фарма Акциенгезельшафт Ингибиторы фдэ и их комбинации для лечения урологических расстройств
WO2007098029A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
EP1984347A1 (en) * 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
EP2705753A1 (en) 2006-08-24 2014-03-12 Surface Logix, Inc. 2-Phenyl-imidazolotriazinone compounds as PDE5 inhibitors
CN101678002A (zh) * 2007-05-08 2010-03-24 先灵公司 使用含有替莫唑胺的静脉注射用配制剂的治疗方法
JP2010532319A (ja) * 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CN113461694A (zh) * 2021-08-05 2021-10-01 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CN113583003A (zh) * 2021-08-05 2021-11-02 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
ZA969888B (en) 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
KR100390612B1 (ko) 1997-04-25 2003-07-07 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TW542719B (en) 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
CN1434825A (zh) * 1999-12-24 2003-08-06 拜尔公司 咪唑并[1,3,5]三嗪酮及其应用

Also Published As

Publication number Publication date
US20050043303A1 (en) 2005-02-24
MXPA02006240A (es) 2003-01-28
KR20020062770A (ko) 2002-07-29
BR0017043A (pt) 2003-01-07
US6803365B2 (en) 2004-10-12
IL150022A0 (en) 2002-12-01
PL356848A1 (en) 2004-07-12
JP2003519150A (ja) 2003-06-17
CA2395548A1 (en) 2001-07-05
CN1434825A (zh) 2003-08-06
AU2842001A (en) 2001-07-09
WO2001047928A2 (de) 2001-07-05
US7091203B2 (en) 2006-08-15
US20030195210A1 (en) 2003-10-16
AU781028B2 (en) 2005-04-28
WO2001047928A3 (de) 2002-05-16
EP1244673A2 (de) 2002-10-02

Similar Documents

Publication Publication Date Title
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
TR200102800T2 (tr) Yeni bileşikler.
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
EA200100731A1 (ru) Фенилфенантридины с ингибирующей фдэ-4 активностью
PT942904E (pt) Derivados de 3-tiocarbamoilpirazol como pesticidas
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
TR200002617T2 (tr) Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
PT998460E (pt) Novos derivados de tetrazole
DE60045508D1 (de) Dalda-analoge und ihre verwendung
BG103219A (bg) Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
UY26426A1 (es) Nuevos compuestos
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
MY120237A (en) Method for the synthesis of quinoline derivatives
DE60043228D1 (de) Herstellungsverfahren von 2-cyanopyridinen
UY26568A1 (es) Nuevos derivados de amidas heterocíclicas
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
PT1064265E (pt) Sintese de 3-amino-2-cloro-4-metilpiridina a partir de malononitrilo e acetona
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
DE59809344D1 (de) Disubstituierte biphenyloxazoline
SE9803107D0 (sv) Novel Compunds
NO20014889D0 (no) Fremgangsmåte for fremstilling av medisinske midler